• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项国际德尔菲专家咨询法研究,旨在确定用于评估抗中性粒细胞胞浆抗体相关性血管炎治疗反应的重要指标。

An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.

机构信息

Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD, USA.

Department of Rheumatology, Policlinico S. Matteo, IRCCS Fondazione, Pavia, Italy; University of Pavia, PhD in Experimental Medicine, Pavia, Italy.

出版信息

Semin Arthritis Rheum. 2022 Aug;55:152021. doi: 10.1016/j.semarthrit.2022.152021. Epub 2022 Apr 28.

DOI:10.1016/j.semarthrit.2022.152021
PMID:35523065
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9262834/
Abstract

OBJECTIVE

ANCA-associated vasculitis (AAV) is characterized by fluctuating levels of disease activity, but no formal criteria exist to measure response to treatment. This Delphi exercise aimed to reach consensus about which measures are considered by patients and physicians to be most important when assessing response to treatment in clinical trials of AAV.

METHODS

An international 3-round online Delphi exercise was conducted. Survey participants included patients with AAV and physicians with expertise in AAV. Survey participants were asked to rate (on a scale of 1-9) the importance of each item when assessing response to treatment in AAV. Items scored 7-9 by ≥70% participants were considered highly important.

RESULTS

89 patients and 176 physicians completed three rounds of the Delphi exercise. The most highly rated items of response involved disease activity [extent of organ involvement, physician global assessment], mortality [survival], and patient-reported outcomes [patient global assessment and health-related quality of life measures]. Achievement of specific BVAS scores were highly rated only by physicians. Items highly rated only by patients included laboratory measures [changes on urinalysis and acute phase reactants], pain, and fatigue. Additional items related to damage and adverse events were highly rated by both groups.

CONCLUSION

There is consensus between patients and physicians on many items considered important to measure when assessing response to treatment in AAV. There are some items considered important by only patients or only physicians. These data will inform the next steps in the development criteria of response to treatment in AAV.

摘要

目的

抗中性粒细胞胞浆抗体相关性血管炎(AAV)的特征是疾病活动水平波动,但目前尚无正式标准来衡量治疗反应。本德尔菲研究旨在就评估 AAV 临床试验中治疗反应时,患者和医生认为哪些措施最重要达成共识。

方法

进行了一项国际性的 3 轮在线德尔菲研究。调查参与者包括 AAV 患者和具有 AAV 专业知识的医生。调查参与者被要求对评估 AAV 治疗反应时的每个项目的重要性进行评分(1-9 分)。得分≥70%的项目被认为非常重要。

结果

89 名患者和 176 名医生完成了 3 轮德尔菲研究。最受重视的反应项目涉及疾病活动度[器官受累程度、医生整体评估]、死亡率[生存]和患者报告的结局[患者整体评估和健康相关生活质量措施]。只有医生高度重视达到特定 BVAS 评分。只有患者高度重视的项目包括实验室指标[尿液分析和急性期反应物的变化]、疼痛和疲劳。两组均高度重视与损害和不良事件相关的其他项目。

结论

患者和医生在评估 AAV 治疗反应时,对许多被认为重要的项目有共识。有些项目仅被患者或医生认为重要。这些数据将为 AAV 治疗反应评估标准的下一步发展提供信息。

相似文献

1
An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.一项国际德尔菲专家咨询法研究,旨在确定用于评估抗中性粒细胞胞浆抗体相关性血管炎治疗反应的重要指标。
Semin Arthritis Rheum. 2022 Aug;55:152021. doi: 10.1016/j.semarthrit.2022.152021. Epub 2022 Apr 28.
2
Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020.开发一种综合结局工具来衡量抗中性粒细胞胞浆抗体相关性血管炎的治疗反应:来自 OMERACT 2020 的混合方法研究。
Semin Arthritis Rheum. 2021 Oct;51(5):1134-1138. doi: 10.1016/j.semarthrit.2021.07.001. Epub 2021 Jul 8.
3
Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process.采用OMERACT流程对抗中性粒细胞胞浆抗体相关血管炎患者报告结局的探索、开发与验证
J Rheumatol. 2015 Nov;42(11):2204-9. doi: 10.3899/jrheum.141143. Epub 2015 Sep 1.
4
Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise.临床医生对抗中性粒细胞胞浆抗体相关性血管炎关键领域的看法:一项德尔菲法研究。
Scand J Rheumatol. 2017 Mar;46(2):112-117. doi: 10.1080/03009742.2016.1188980. Epub 2016 Jul 20.
5
Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.验证抗中性粒细胞胞浆抗体相关性血管炎患者报告结局(AAV-PRO)问卷。
Ann Rheum Dis. 2018 Aug;77(8):1157-1164. doi: 10.1136/annrheumdis-2017-212713. Epub 2018 Apr 25.
6
OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.抗中性粒细胞胞浆抗体相关性血管炎患者报告结局指标的 OMERACT 认可。
J Rheumatol. 2017 Oct;44(10):1529-1535. doi: 10.3899/jrheum.161139. Epub 2017 Sep 1.
7
Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review.用于抗中性粒细胞胞浆抗体相关性血管炎的结局测量工具的心理计量学特性:系统文献回顾。
Rheumatology (Oxford). 2022 Nov 28;61(12):4603-4618. doi: 10.1093/rheumatology/keac175.
8
Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment.影响抗中性粒细胞胞浆抗体相关性血管炎患者报告结局的因素:患者整体评估的相关性。
Semin Arthritis Rheum. 2022 Oct;56:152048. doi: 10.1016/j.semarthrit.2022.152048. Epub 2022 Jun 14.
9
Using Delphi methodology in the development of a new patient-reported outcome measure for stroke survivors with visual impairment.运用 Delphi 法为视觉障碍卒中幸存者开发新的患者报告结局测量工具。
Brain Behav. 2018 Jan 17;8(2):e00898. doi: 10.1002/brb3.898. eCollection 2018 Feb.
10
A Dutch consensus statement on the diagnosis and treatment of ANCA-associated vasculitis.荷兰关于抗中性粒细胞胞浆抗体相关性血管炎的诊断和治疗的共识声明。
Neth J Med. 2020 Mar;78(2):71-82.

引用本文的文献

1
Granulomatosis with polyangiitis: clinical characteristics and updates in diagnosis.肉芽肿性多血管炎:临床特征与诊断进展
Front Med (Lausanne). 2024 Aug 27;11:1369233. doi: 10.3389/fmed.2024.1369233. eCollection 2024.
2
How is the patient perspective captured in ANCA-associated vasculitis research? An integrative review.在抗中性粒细胞胞浆抗体相关性血管炎研究中如何体现患者视角?一项综合综述。
Rheumatol Adv Pract. 2023 Oct 24;7(3):rkad092. doi: 10.1093/rap/rkad092. eCollection 2023.
3
Challenges of defining renal response in ANCA-associated vasculitis: call to action?

本文引用的文献

1
Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020.开发一种综合结局工具来衡量抗中性粒细胞胞浆抗体相关性血管炎的治疗反应:来自 OMERACT 2020 的混合方法研究。
Semin Arthritis Rheum. 2021 Oct;51(5):1134-1138. doi: 10.1016/j.semarthrit.2021.07.001. Epub 2021 Jul 8.
2
Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review.使用和报告抗中性粒细胞胞质抗体相关性血管炎随机试验的结局指标:系统文献回顾。
Semin Arthritis Rheum. 2020 Dec;50(6):1314-1325. doi: 10.1016/j.semarthrit.2020.09.010. Epub 2020 Sep 29.
3
抗中性粒细胞胞浆抗体相关性血管炎中定义肾脏反应的挑战:行动呼吁?
Clin Kidney J. 2023 Jan 11;16(6):965-975. doi: 10.1093/ckj/sfad009. eCollection 2023 Jun.
Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development.
OMERACT 中的共识建立:德尔菲法在核心结局集开发中的应用建议。
J Rheumatol. 2019 Aug;46(8):1041-1046. doi: 10.3899/jrheum.181094. Epub 2019 Feb 15.
4
Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.使用 OMERACT 筛选器 2.1 进行仪器选择:OMERACT 方法学。
J Rheumatol. 2019 Aug;46(8):1028-1035. doi: 10.3899/jrheum.181218. Epub 2019 Feb 1.
5
Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health.更新用于抗中性粒细胞胞浆抗体相关性血管炎的 OMERACT 核心域集:使用国际功能、残疾和健康分类的患者视角。
J Rheumatol. 2019 Oct;46(10):1415-1420. doi: 10.3899/jrheum.181073. Epub 2019 Feb 1.
6
Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.验证抗中性粒细胞胞浆抗体相关性血管炎患者报告结局(AAV-PRO)问卷。
Ann Rheum Dis. 2018 Aug;77(8):1157-1164. doi: 10.1136/annrheumdis-2017-212713. Epub 2018 Apr 25.
7
Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise.临床医生对抗中性粒细胞胞浆抗体相关性血管炎关键领域的看法:一项德尔菲法研究。
Scand J Rheumatol. 2017 Mar;46(2):112-117. doi: 10.1080/03009742.2016.1188980. Epub 2016 Jul 20.
8
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.利妥昔单抗与硫唑嘌呤用于抗中性粒细胞胞浆抗体相关性血管炎的维持治疗。
N Engl J Med. 2014 Nov 6;371(19):1771-80. doi: 10.1056/NEJMoa1404231.
9
Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's).简要报告:在肉芽肿伴多血管炎(韦格纳氏)中,患者疾病活动的整体评估的价值。
Arthritis Rheumatol. 2014 Feb;66(2):428-32. doi: 10.1002/art.38248.
10
The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis.用于抗中性粒细胞胞浆抗体相关性血管炎临床试验的 OMERACT 核心结局测量集。
J Rheumatol. 2011 Jul;38(7):1480-6. doi: 10.3899/jrheum.110276.